Lowe G D, Dunlop D J, Lawson D H, Pollock J G, Watt J K, Forbes C D, Prentice C R, Drummond M M
Angiology. 1982 Jan;33(1):46-50. doi: 10.1177/000331978203300107.
In a randomized double-blind trial, patients with ischemic rest pain of the leg received 8 days of treatment with intravenous injections of the defibrinating agent, ancrod (Arvin) or saline. Plasma fibrinogen, plasma viscosity, and blood viscosity were significantly reduced during ancrod therapy. After 27 patients had completed treatment, sequential analysis showed no preference for either therapy. In each group two-thirds of the patients claimed improvement in pain after treatment. There were no significant differences between treatment groups in analgesic consumption, Doppler systolic pressure ratio, or surgical intervention in the 6 months following treatment. We conclude that in patients with ischemic rest pain, ancrod therapy is not superior to placebo injections, and that the effect of placebo treatment is considerable.
在一项随机双盲试验中，患有腿部缺血性静息痛的患者接受了为期8天的静脉注射去纤维蛋白剂安克洛酶（Arvin）或生理盐水的治疗。在安克洛酶治疗期间，血浆纤维蛋白原、血浆粘度和血液粘度均显著降低。27例患者完成治疗后，序贯分析显示对两种治疗方法无偏好。每组中有三分之二的患者称治疗后疼痛有所改善。治疗组之间在治疗后6个月的止痛药物消耗量、多普勒收缩压比值或手术干预方面无显著差异。我们得出结论，对于患有缺血性静息痛的患者，安克洛酶治疗并不优于安慰剂注射，且安慰剂治疗的效果相当可观。
